Multiple myeloma following essential thrombocythemia

Leuk Lymphoma. 1995 Dec;20(1-2):177-9. doi: 10.3109/10428199509054773.

Abstract

The association of essential thrombocythemia (ET) and multiple myeloma (MM) is exceedingly rare, with only four such cases reported in the literature until now. In this paper, a patient is reported who developed IgA-lambda MM more than five years after the diagnosis of ET, for which she had received alpha interferon and radioactive phosphor (32P). She died shortly afterwards despite melphalan and prednisone therapy. In four of the five patients in whom the above association has been reported, including the present one, MM appeared some time after ET was initially recognized, with three of them having received alkylating drugs as their treatment for ET. MM was heterogeneous with respect to the M--component type and the clinical course. The possible etiological & pathogenetic link between both these entities is discussed.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Female
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin M / blood
  • Immunoglobulin lambda-Chains / blood
  • Interferon-alpha / therapeutic use
  • Multiple Myeloma / complications*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy
  • Phosphorus Radioisotopes / therapeutic use
  • Thrombocytosis / complications*
  • Thrombocytosis / pathology
  • Thrombocytosis / therapy

Substances

  • Immunoglobulin A
  • Immunoglobulin M
  • Immunoglobulin lambda-Chains
  • Interferon-alpha
  • Phosphorus Radioisotopes